Second Donation from Volunteer Hematopoietic Stem Cell Donors in Taiwan Tso-Fu Wang(1), Shu-Huey Chen(1), Shang-Hsien Yang(1), Chu-Yu Chang(2), Ya-Wen.

Slides:



Advertisements
Similar presentations
Hematopoietic Stem Cell Transplantation Lynn Savoie September 30, 2006.
Advertisements

Empowering hospital patients as partners in their diagnosis and treatment The example of bone marrow transplantation Hildegard Greinix Medical University.
Questions and Answers about Bone Marrow Stem Cell Transplantation prepared by the Armenian Bone Marrow Donor Registry.
Miguel Concepción Class of 2009 UMass Medical School Educational Presentation for Middle & High School Students.
18 and Swabbin: Never Too Young. The Delete Blood Cancer Mission Our mission is our name. We work to “Delete Blood Cancer” by inspiring as many people.
CLINICAL CODING FOR BM & PBSC TRANSPLANT PROCEDURES Dr Kim Orchard – Transplant Director Carol Hurlock – Data Manager Wessex Blood and Marrow Transplantation.
Blood Product Reimbursement Report 4 th QuarterNovember 2009Volume 1, Number This information is provided as a service to assist hospitals and other.
Association of ABO Incompatibility with RBC Indices of Cord Blood Unit Shu-Huey Chen, Marie Lin, Kuo-Liang Yang, Teng-Yi Lin, His-Hsiu Tsai, Shang-Hsien.
An Overview of the Bone Marrow Donation Process The Icla da Silva Foundation, Inc. Internet:
The basics of Marrow Things to know.... Reasons to hold a marrow drive: ›Patient Focused ›Potential for large minority turnout ›Saturn National Donor.
5-Azacitidine For Myelodysplasia Before Allogeneic Hematopoietic Cell Transplantation Field T et al. Bone Marrow Transplant 2009:[Epub ahead of print].
The role of post granulocyte colony-stimulating factor white blood cell counts in predicting the mobilization adverse events and yields Shu-Huey Chen1,2.
The Impact of Circulation Access in Allogeneic Peripheral Blood Stem Cell Harvest Shang-Hsien Yang1, Tso-Fu Wang2,3, Shu-Hui Wen4, Sung-Chao Chu3, Ruey-Ho.
DONOR LYMPHOCYTE INFUS I ON (DLI) Dr. Serdar ŞIVGIN February 2011 Kayseri.
Reduced-Intensity Conditioning (RIC) and Allogeneic Stem Cell Transplantation (allo-SCT) for Relapsed/Refractory Hodgkin Lymphoma (HL) in the Brentuximab.
Taiwan Unrelated Donor PBSC Harvest Experience Shu-Huey Chen Hualien Tzu-Chi General Hospital.
Safety and efficacy of hematopoietic stem cell collection from mobilized peripheral blood in unrelated volunteers: 12 years of single-center experience.
Established in 2012, BTMOC is more than a student-led program on college and university campuses. It is a burgeoning social movement to expand the reach.
Bone Marrow Donation Zach Siefker HNRS 1010.
Creating Connections. Saving Lives. ™ NATIONAL MARROW DONOR PROGRAM ® Regulation of PBSC and DLI from Unrelated Donors: Meeting the Needs of the U.S. Public.
Bone Marrow Donation. What is Bone marrow?  flexible spongy tissue in the interior of bones such as your hip and thigh.  constitutes 4% of the total.
Volunteer Training Double Red Cell Donation COL-COPY (AA) This training material is a template which Blood centers can use to help draft their training.
Behaviors Affecting Bone Health and vitamin D level among Adolescent Females Al-Raddadi Rajaa, Bahijri Suhad, Al-Raddadi Zeyad, Borai Anwar Research Project.
Case report Sudden blastic transformation in patient with chronic myeloid leukemia treated with imatinib mesylate Mehrdad Payandeh,MD Hematology, Medical.
HAPLOIDENTICAL STEM CELL TRANSPLANT
Abstract Immune Reconstitution and Clinical Outcome After Donor Lymphocyte Infusion for Relapsed Disease After Reduced-Intensity Allogeneic Hematopoietic.
Clinical Infectious Diseases 2012;55(6):764–70 Jan Vydra,1 Ryan M. Shanley,2 Ige George,1 Celalettin Ustun,1 Angela R. Smith,4 Daniel J. Weisdorf,1 and.
Peripheral-Blood Stem Cells versus Bone Marrow from Unrelated Donors N Engl J Med 2012;367: R3 Sunhee park/Prof. Kyung-sam cho.
Bone Marrow Transplant
Alexander H. Schmidt, Thilo Mengling, Camila J
Autologous Peripheral Blood Stem Cell Rescue. Multiple Myeloma.
Lenograstim Chemical Formula : C840-H1330-N222-O242-S8
No:18 Red Cell Contamination In Leukapheresis Product-
at First Pavlov State Medical University of Saint-Petersburg, Russia
Patient Characteristic
Bone Marrow Graft-versus-Host Disease: Evaluation of Its Clinical Impact on Disrupted Hematopoiesis after Allogeneic Hematopoietic Stem Cell Transplantation 
Peripheral Blood Stem Cell Rescue. Multiple Myeloma.
Adverse events among 2408 unrelated donors of peripheral blood stem cells: results of a prospective trial from the National Marrow Donor Program by Michael.
Selective Depletion of αβ T Cells and B Cells for Human Leukocyte Antigen– Haploidentical Hematopoietic Stem Cell Transplantation. A Three-Year Follow-Up.
Recovery and Safety Profiles of Marrow and PBSC Donors: Experience of the National Marrow Donor Program  John P. Miller, Elizabeth H. Perry, Thomas H.
Influence of Stem Cell Source on Outcomes of Allogeneic Reduced-Intensity Conditioning Therapy Transplants Using Haploidentical Related Donors  Kenneth.
Related PBSC Donors Experience Higher Levels of Pain and Donation-Related Symptoms and Less Complete Rates of Recovery Compared to Unrelated Donors:
Prophylactic Donor Lymphocyte Infusion (DLI) Followed by Minimal Residual Disease and Graft-versus-Host Disease–Guided Multiple DLIs Could Improve Outcomes.
Peripheral Blood Grafts from Unrelated Donors Are Associated with Increased Acute and Chronic Graft-versus-Host Disease without Improved Survival  Mary.
Erratum to “Increased Type 1 Immune Response in the Bone Marrow Immune Microenvironment of Patients with Poor Graft Function after Allogeneic Hematopoietic.
Donor-to-Recipient ABO Mismatch Does Not Impact Outcomes of Allogeneic Hematopoietic Cell Transplantation Regardless of Graft Source  Sharat Damodar,
Zaja F et al. Proc ASH 2010;Abstract 966.
The Effect of Different Harvest Strategies on the Nucleated Cell Yields of Bone Marrow Collection  Tso-Fu Wang, Sung-Chao Chu, Shu-Huey Chen, Kuan-Po.
Hematopoietic Cell Transplantation as Curative Therapy for Patients with Myelofibrosis: Long-Term Success in all Age Groups  H. Joachim Deeg, Christopher.
Factors Associated with Peripheral Blood Stem Cell Yield in Volunteer Donors Mobilized with Granulocyte Colony-Stimulating Factors: The Impact of Donor.
Recovery of Unrelated Donors of Peripheral Blood Stem Cells versus Recovery of Unrelated Donors of Bone Marrow: A Prespecified Analysis from the Phase.
Can Only Partial T-Cell Depletion of the Graft before Hematopoietic Stem Cell Transplantation Mitigate Graft-versus-Host Disease While Preserving a Graft-versus-
Successful hematopoietic stem cell mobilization and apheresis collection using plerixafor alone in sickle cell patients by Erica B. Esrick, John P. Manis,
Predonation Health-Related Quality of Life Scores Predict Time to Recovery in Hematopoietic Stem Cell Donors  Annelies Billen, J. Alejandro Madrigal,
Clinical Endpoints in Allogeneic Hematopoietic Stem Cell Transplantation Studies: The Cost of Freedom  Haesook T. Kim, Philippe Armand  Biology of Blood.
Two Partial T Cell Depletion Strategies for Unrelated Donor Peripheral Stem Cell Transplantation are Associated with Excellent Outcomes for Pediatric.
Introduction. Title: Activities and Outcomes of Hematopoietic Cell Transplantation in Japan.
HLA-Allele Matched Unrelated Donors Compared to HLA-Matched Sibling Donors: Role of Cell Source and Disease Risk Category  Ann Woolfrey, Stephanie J.
Volume 2(Supplement 1):46-49
Donation Activities and Product Integrity in Unrelated Donor Allogeneic Hematopoietic Transplantation: Experience of the National Marrow Donor Program 
Low Serum Levels of Total Rabbit-IgG Is Associated with Acute Graft-Versus-Host Disease after Unrelated Donor Hematopoietic Stem Cell Transplantation:
Abnormalities of the Bone Marrow Immune Microenvironment in Patients with Prolonged Isolated Thrombocytopenia after Allogeneic Hematopoietic Stem Cell.
Acute toxicities of unrelated bone marrow versus peripheral blood stem cell donation: results of a prospective trial from the National Marrow Donor Program.
Yuri Fedoriw, T. Danielle Samulski, Allison M. Deal, Cherie H
Hematopoietic cell transplantation from related and unrelated donors after minimal conditioning as a curative treatment modality for severe paroxysmal.
Pain. Pain. (A) Skeletal pain experienced by bone marrow (BM) and peripheral blood stem cell (PBSC) donors at baseline, during the pericollection period,
Increased Type 1 Immune Response in the Bone Marrow Immune Microenvironment of Patients with Poor Graft Function after Allogeneic Hematopoietic Stem Cell.
Mary Eapen  Biology of Blood and Marrow Transplantation 
Graft Monocytic Myeloid-Derived Suppressor Cell Content Predicts the Risk of Acute Graft-versus-Host Disease after Allogeneic Transplantation of Granulocyte.
Donor Experiences of Second Marrow or Peripheral Blood Stem Cell Collection Mirror the First, but CD34+ Yields Are Less  David F. Stroncek, Bronwen E.
Presentation transcript:

Second Donation from Volunteer Hematopoietic Stem Cell Donors in Taiwan Tso-Fu Wang(1), Shu-Huey Chen(1), Shang-Hsien Yang(1), Chu-Yu Chang(2), Ya-Wen Chiu(2), Teng-Yi Lin(1), Ming-Hwang Shyr(1), Kuo-Liang Yang(2) (1)Hualien Tzu-Chi General Hospital Taiwan; (2)Buddhist Tzu-Chi Stem Cell Center Introduction Occasionally, unrelated hematopoietic stem cell donors may be asked to provide subsequent donations of stem cells or lymphocytes. In this study, we evaluated the frequency of and reasons for a second donation and whether donors prefer peripheral blood stem cell (PBSC) collection or bone marrow (BM) harvest. In addition, we compared the yields of and side effects associated with twice BM harvest. Materials and methods Donor characteristics, reasons for the second donation, type of second donation, and yield of BM stem cell product were abstracted from medical records. The psychosocial and physical experiences of donors who underwent two different hematopoietic stem cell collection procedures (BM and PBSC) and their preference for one procedure over the other were collected via a self-reported questionnaire. Among donors who underwent two bone marrow harvests, we compared the yields of and the side effects associated with the first and second harvest. The side effects associated with BM and PBSC harvest were compared by Chi- square test. The yield of subsequent BM harvests was compared by the Wilcoxon test. A P value less than 0.05% was considered significant. Results Among the 1738 donors analyzed, 72 had made more than one donation. The procedures included lymphocyte donations in 55 donors, BM harvest in 9 donors, and PBSC collection in 8 donors. A total of 13 donors underwent both BM and peripheral blood stem cell (PBSC) donations and 4 donors underwent two BM harvests. Five of the 17 donors donated the second collection of hematopoietic stem cells to different patients and 12 of the 17 donors donated stem cells to the same patient on both occasions. The indications for the second donation from these 12 donors were graft failure (5 of 12; 41.7 %) and disease relapse (7 of 12; 58.3%). The median recovery time associated with PBSC (1 day) was significantly shorter than that associated with BM harvest (7 days) (p=0.0083). Although most of the donors who underwent both procedures felt that BM harvest was more physically demanding, caused more pre-procedural anxiety, was more time consuming, and was more inconvenient than PBSC collection, 63.6% of them preferred BM donation. There was no significant difference in yield of stem cells between the first and second BM harvests (p=0.25). In addition, there were no significant differences in the incidence of side effects or recovery time between the first and second BM donation. Approximately 30% (5/15) of the donors had difficulty before agreeing to donate hematopoietic stem cells a second time. Among the 17 donors, 10 encountered disagreement from their relatives or friends. TNC: total nucleated cell, V: harvest volume, Density=TNC/Volume, BH: body height, BW: body weight, 1: first harvest, 2: second harvest Table 2 Characteristics and BM yield of 4 donors with twice BM harvest Conclusions Table 1. Side Effect of BM vs PBSC donation Although the case number in our study is relatively small, more donors’ preference for BM harvest over PBSC collection is different from that reported in previous studies despite similar side effects. Discomfort of PBSC apheresis procedure can explain this result partially. We decrease the process volume in low body weight donors and use skilled medical staffs to establish vascular access and more aggressive supplement of calcium gluconate to decrease adverse events associated with apheresis procedure. Percentagep value Headache BM0(0/13) PB23.1(3/13) Fatigue BM46.2(6/13) PB84.6(11/13) Bone pain BM69.2(9/13) PB46.2(6/13) Dizziness BM23.1(3/13) N/A PBN/A Insomnia BMN/A PB7.7(1/13) Vomiting BM0(0/13) N/A PBN/A Difficulty in walking BM38.5(5/13) N/A PBN/A Median recovery time (day) BM PB1 DonorTNC1TNC2V(ml)1V(ml)2Density1Density2Age1BH1BW1Interval 1,male m 2,male m 3,male m 4,male m Median P valueP=0.25P=0.375P=0.25